A new breakthrough in the treatment of endometriosis is set to revolutionise care for patients in Wales and England. The National Institute for Health and Care Excellence (Nice) has given the green light for the daily pill, Ryeqo, which is designed to help over 1,000 women annually who suffer from this debilitating condition. Following approval, the Welsh Government has confirmed that Ryeqo will soon be available on the NHS in Wales, offering a promising alternative for those struggling with endometriosis.
Ryeqo, scientifically known as Relugolix–estradiol–norethisterone, represents a significant milestone as the first long-term daily treatment approved specifically for endometriosis. This combination pill works by blocking hormones contributing to the condition while providing essential hormone replacement therapy. Unlike injectable treatments that may initially worsen symptoms, Ryeqo offers the convenience of home use, faster efficacy, and eliminates the need for frequent clinic visits. However, access to the pill will be limited to patients who have not responded to previous medical or surgical interventions.
Endometriosis UK has pointed out that while Ryeqo presents a promising option, it may only be suitable for a small fraction of the 1.5 million women affected by the disease in the UK. The treatment is priced at £72 for a 28-day supply (excluding VAT) and was initially rejected by Nice. Nevertheless, the manufacturer, Gedeon Richter, provided additional evidence addressing concerns over effectiveness and cost-efficiency, leading to the pill’s eventual approval for NHS prescription.
Helen Knight, director of medicines evaluation at Nice, highlighted the potential impact of Ryeqo in transforming endometriosis management by empowering patients with greater control over their treatment. The convenience of a daily oral tablet offers flexibility and ease of use, particularly beneficial for individuals planning for pregnancy or managing treatment-related side effects. This advancement not only enhances patients’ quality of life but also alleviates pressure on NHS resources.
Endometriosis is a chronic condition characterised by the growth of uterine-like cells in other parts of the body, causing symptoms such as severe pain, heavy menstrual bleeding, fatigue, and fertility issues. Despite affecting a significant number of women in the UK, diagnosing endometriosis typically takes around nine years from the onset of symptoms. The complexity of diagnosis stems from symptom overlap with other conditions like fibroids, pelvic inflammatory disease, and irritable bowel syndrome.
Dr Sue Mann, NHS national clinical director for women’s health, emphasised the importance of Ryeqo as a groundbreaking treatment for endometriosis. By granting women the ability to manage their health from home, this innovative therapy offers a more patient-centric approach, reducing the reliance on frequent medical appointments. The availability of Ryeqo on the NHS heralds a new era in endometriosis care, aiming to provide effective and convenient solutions for those affected by the condition.
In conclusion, the introduction of Ryeqo on the NHS in Wales represents a significant advancement in the management of endometriosis. With its potential to improve treatment outcomes and patient experience, this daily pill offers hope and relief to individuals grappling with the challenges of this distressing condition. As healthcare continues to evolve, innovations like Ryeqo underscore the importance of tailored, accessible, and patient-centred solutions in addressing complex medical conditions.